By flow cytometry analysis of primary MM cells derived from patients before and after treatment, we saw that the levels of some MM-related markers (for example CD56) have declined, probably meaning that the cells that express them were eliminated by the treatment. Here, NCAM1 is linked to Miyoshi myopathy.